Our Solution

Home / Our Solution

gWinSanTor is developing a proprietary first-in-class therapy to prevent and reverse nerve damage. WinSanTor has identified a class of compounds, and more importantly, the discovery of a novel pathway resulting in neuroprotection and neuroregeneration of degenerating neurons. Our lead/first compound, WST57, is a well-characterized previously approved drug with an established safety history that has been used for many years against an unrelated indication.  This allows WinSanTor a direct path to market, reducing development time and cost with a drug that is patented as a new formulation with novel indications.

WST57 prevents, mitochondrial dysfunction, nerve fiber depletion and sensory loss in several distinct animal models of peripheral neuropathy.

We are strategically expanding WST57’s indications to all neuropathies, such as chemo induced and HIV related. Additionally, WST57 is just one compound we are investigating in a family of promising compounds that we have exclusive world wide rights to.

Discovery. Several hundred compounds were screened in an in vitro assay using sensory neurons from normal or diabetic adult rats as part of a NIH/JDRF-funded program to identify novel uses for existing drugs. From these preclinical studies we selected one compound as our lead candidate due to its efficacy profile and strong safety history.  WST57 is a well-characterized API that has been used since the early 1980’s to treat unrelated (smaller market) indications.

Proof of Concept: WinSanTor has established significant preclinical efficacy showing WST57 prevents, mitochondrial dysfunction, nerve fiber depletion and sensory loss in several distinct animal models of peripheral neuropathy. Evidence of efficacy against diabetic neuropathy has been obtained in STZ-diabetic mice and STZ-diabetic rat, in 2 treatment paradigms (prevention and reversal) and animal models of type 2 diabetes (db/db and ob/ob strains). WST57 does not affect the diabetic state and no side effects were noted.2

Mechanism:  We have accumulated strong experimental evidence that supports our hypothesis that, as part of a normal homeostatic system, adult peripheral neurons are under constant endogenous constraint that serves to suppress the growth capacity and plasticity of axon terminals.  In a disease state, blocking this system using selective antagonists enhances growth and plasticity, thereby offering a novel therapeutic approach to reversing early diabetic neuropathy. This platform technology enables WinSanTor to develop a class of compounds that overcome endogenous growth constraints to promote nerve re-growth after injuries such as by diabetes. Our lead candidate is an established compound with an established safety profile that may allow a direct path to market, thereby reducing development time and costs.